View
Page
"The negative results from Circassia’s (9.3% owned by Innovations) Cat-SPIRE Phase III trial is disappointing, with a negative read-across to Circassia’s earlier-stage programmes in Grass, Birch, Ragweed, and House Dust Mites allergy. We highlighted the Cat-SPIRE result as a significant risk factor in our recent report ‘Premium justified, but some near-term caution’ on 27th May. However, we continue to believe that Circassia’s respiratory development portfolio (acquired with the £100m acquisition of Prosonix) has significant..." note out by N+1 Singer this morning, on research tree
Welcome to the new Imperial Innov stream forum! Messages posted in the Imperial Innov stream will be logged here for posterity.
Latest from the Community...
Latest from the Community...
Latest from the Community...
